CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Regulation FD disclosure
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Open-market sale Chief People Officer sold 29,814 shares at $4.17 ($124,414)
- 4 Open-market sale President and CEO sold 180,677 shares at $4.17 ($753,965)
- 4 Open-market sale Chief Legal Officer sold 40,102 shares at $4.17 ($167,346)
- 4 Open-market sale SVP, Regulatory Affairs sold 25,311 shares at $4.17 ($105,623)
- 4 Open-market sale Chief Financial Officer sold 58,254 shares at $4.17 ($243,094)
- 4 Open-market sale Chief Commercial Officer sold 15,741 shares at $4.17 ($65,687)
- 4 Open-market sale Chief Operating Officer sold 45,791 shares at $4.17 ($191,086)
- 4 Grant or award Chief Development Officer acquired 50,000 shares (grant or award)
Page 4 of 35 · 689 filings